Neurologia medico-chirurgica
Online ISSN : 1349-8029
Print ISSN : 0470-8105
ISSN-L : 0470-8105

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Neurointensive Care of Traumatic Brain Injury Patients Based on Coagulation and Fibrinolytic Parameter Monitoring
Ryuta NAKAEYasuo MURAIYasuhiro TAKAYAMAKaoru NAMATAMEYoshiyuki MATSUMOTOTakahiro KANAYAYu FUJIKIHidetaka ONDAGo SUZUKIJunya KANEKOTakashi ARAKIYasutaka NAOEHidetaka SATOKyoko UNEMOTOAkio MORITAHiroyuki YOKOTAShoji YOKOBORI
著者情報
ジャーナル オープンアクセス 早期公開
電子付録

論文ID: 2022-0226

この記事には本公開記事があります。
詳細
抄録

Coagulopathy, a common complication of traumatic brain injury (TBI), is characterized by a hypercoagulable state developing immediately after injury, with hyperfibrinolysis and bleeding tendency peaking 3 h after injury, followed by fibrinolysis shutdown. Reflecting this timeframe, the coagulation factor fibrinogen is first consumed and then degraded after TBI, its concentration rapidly decreasing by 3 h post-TBI. The fibrinolytic marker D-dimer reaches its maximum concentration at the same time. Hyperfibrinolysis in the acute phase of TBI is associated with poor prognosis via hematoma expansion. In the acute phase, the coagulation and fibrinolysis parameters must be monitored to determine the treatment strategy. The combination of D-dimer plasma level at admission and the level of consciousness upon arrival at the hospital can be used to predict the patients who will "talk and deteriorate." Fibrinogen and D-dimer levels should determine case selection and the amount of fresh frozen plasma required for transfusion. Surgery around 3 h after injury, when fibrinolysis and bleeding diathesis peak, should be avoided if possible. In recent years, attempts have been made to estimate the time of injury from the time course of coagulation and fibrinolysis parameter levels, which has been particularly useful in some cases of pediatric abusive head trauma patients.

Fullsize Image
著者関連情報
© 2022 The Japan Neurosurgical Society

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top